Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 105 articles:
HTML format



Single Articles


    December 2022
  1. LATIF MU, Schmidt GE, Mercan S, Rahman R, et al
    NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
    Gut. 2022;71:2561-2573.
    PubMed     Abstract available


  2. RAO J, Wang H, Ni M, Wang Z, et al
    FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.
    Gut. 2022;71:2539-2550.
    PubMed     Abstract available


    November 2022
  3. TAN Z, Chiu MS, Yang X, Yue M, et al
    Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Gut. 2022 Nov 30:gutjnl-2022-327133. doi: 10.1136/gutjnl-2022-327133.
    PubMed     Abstract available


  4. BAJAJ JS, Pena-Rodriguez M, La Reau A, Phillips W, et al
    Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
    Gut. 2022 Nov 7. pii: gutjnl-2022-328403. doi: 10.1136/gutjnl-2022-328403.
    PubMed     Abstract available


  5. THEVENOT T, Desmarets M, Weil D, Di Martino V, et al
    Diameter of the shunt: the missing link in the appraisal of pTIPS in patients with cirrhosis with previous hepatic encephalopathy.
    Gut. 2022 Nov 3. pii: gutjnl-2022-328761. doi: 10.1136/gutjnl-2022-328761.
    PubMed    


  6. DUFOUR JF, Marjot T, Becchetti C, Tilg H, et al
    COVID-19 and liver disease.
    Gut. 2022;71:2350-2362.
    PubMed     Abstract available


  7. KASPER P, Lang S, Demir M, Steffen HM, et al
    Optimising the management of cardiovascular comorbidities in NAFLD patients: it's time to (re-) act!
    Gut. 2022;71:2365-2366.
    PubMed    


    September 2022
  8. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    PubMed    


  9. RUDLER M, Hernandez-Gea V, Procopet BD, Giraldez A, et al
    Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
    Gut. 2022 Sep 9. pii: gutjnl-2022-326975. doi: 10.1136/gutjnl-2022-326975.
    PubMed     Abstract available


  10. ZHAO Y, Yeo YH, Samaan J, Lv F, et al
    Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
    Gut. 2022 Sep 5. pii: gutjnl-2022-328188. doi: 10.1136/gutjnl-2022-328188.
    PubMed    


  11. BYRNE CD, Targher G
    Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Gut. 2022;71:1695-1696.
    PubMed    


  12. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    PubMed     Abstract available


    August 2022

  13. Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2022;71:e9.
    PubMed    


  14. LIU N, Wang X, Steer CJ, Song G, et al
    MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells.
    Gut. 2022;71:1642-1655.
    PubMed     Abstract available


  15. ZHOU L, Yu KH, Wong TL, Zhang Z, et al
    Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.
    Gut. 2022;71:1656-1668.
    PubMed     Abstract available


  16. REVIA S, Seretny A, Wendler L, Banito A, et al
    Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Gut. 2022;71:1613-1628.
    PubMed     Abstract available


  17. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    PubMed    


    July 2022
  18. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    PubMed    


  19. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    PubMed     Abstract available


  20. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    PubMed     Abstract available


  21. GRACIA-SANCHO J, Dufour JF
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.
    PubMed    


  22. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    PubMed    


  23. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available


    June 2022
  24. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    PubMed    


  25. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.
    PubMed    


  26. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available


  27. MITHIEUX G
    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.
    PubMed    


  28. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
    Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
    Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
    PubMed     Abstract available


  29. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    PubMed    


    May 2022
  30. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available


  31. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
    British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
    Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
    PubMed     Abstract available


  32. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    PubMed     Abstract available


  33. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
    Hepatic p63 regulates glucose metabolism by repressing SIRT1.
    Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
    PubMed     Abstract available


  34. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
    PubMed    


  35. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    PubMed     Abstract available


  36. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
    Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Gut. 2022;71:983-990.
    PubMed     Abstract available


    April 2022
  37. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
    PubMed    


  38. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    PubMed    


  39. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.
    PubMed    


  40. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    PubMed     Abstract available


  41. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    PubMed     Abstract available


    March 2022
  42. ZHANG C, Li J, Cheng Y, Meng F, et al
    Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
    Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
    PubMed     Abstract available


  43. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    PubMed    


  44. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    PubMed     Abstract available


  45. RHA MS, Han JW, Koh JY, Lee HS, et al
    Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
    Gut. 2022;71:605-615.
    PubMed     Abstract available


    February 2022
  46. LU LG, Zhou ZL, Wang XY, Liu BY, et al
    PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
    PubMed     Abstract available


  47. SUN S, Yang Q, Zhou Q, Cao W, et al
    Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
    Gut. 2022;71:443-445.
    PubMed    


  48. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    PubMed    


  49. FRANCQUE S, Wong VW
    NAFLD in lean individuals: not a benign disease.
    Gut. 2022;71:234-236.
    PubMed    


  50. YOUNES R, Govaere O, Petta S, Miele L, et al
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Gut. 2022;71:382-390.
    PubMed     Abstract available


  51. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
    Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
    Gut. 2022;71:402-414.
    PubMed     Abstract available


    January 2022
  52. TIAN S, Chu Y, Hu J, Ding X, et al
    Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT.
    Gut. 2022 Jan 27. pii: gutjnl-2021-325137. doi: 10.1136/gutjnl-2021-325137.
    PubMed     Abstract available


  53. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
    CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
    PubMed     Abstract available


  54. BELLOMO G, Rainer C, Quaranta V, Astuti Y, et al
    Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325272. doi: 10.1136/gutjnl-2021-325272.
    PubMed     Abstract available


  55. JI F, Zhang J, Liu N, Gu Y, et al
    Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
    Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
    PubMed     Abstract available


  56. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    PubMed    


  57. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
    Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
    Gut. 2022;71:148-155.
    PubMed     Abstract available


  58. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Gut. 2022;71:156-162.
    PubMed     Abstract available


    December 2021
  59. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
    Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
    PubMed     Abstract available


  60. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    PubMed     Abstract available


  61. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    PubMed    


  62. BANG JY, Ward TJ, Guirguis S, Krall K, et al
    Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
    Gut. 2021;70:2224-2226.
    PubMed    


  63. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
    Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
    Gut. 2021;70:2283-2296.
    PubMed     Abstract available


  64. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    PubMed     Abstract available


  65. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
    Uphill or downhill bleeding?
    Gut. 2021;70:2282-2348.
    PubMed    


    November 2021
  66. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
    PubMed    


    October 2021
  67. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    PubMed     Abstract available



  68. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.
    PubMed    


  69. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    PubMed     Abstract available


  70. LIU T, Tan J, Wu M, Fan W, et al
    High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
    Gut. 2021;70:1965-1977.
    PubMed     Abstract available


  71. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    PubMed     Abstract available


  72. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
    Diet-refractory NASH in an elderly woman.
    Gut. 2021;70:1924-1945.
    PubMed    


    September 2021
  73. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
    PubMed    


  74. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
    Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Gut. 2021;70:1758-1767.
    PubMed     Abstract available


    August 2021
  75. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available


  76. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    PubMed     Abstract available


  77. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    PubMed     Abstract available


    July 2021
  78. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    PubMed     Abstract available


  79. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    PubMed     Abstract available


  80. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
    Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    Gut. 2021;70:1299-1308.
    PubMed     Abstract available


    June 2021
  81. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    PubMed    


  82. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
    PubMed    


    May 2021
  83. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available


  84. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed    


  85. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021;70:962-969.
    PubMed     Abstract available


    April 2021
  86. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    PubMed     Abstract available


  87. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    PubMed     Abstract available


  88. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    PubMed     Abstract available


    March 2021
  89. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    PubMed     Abstract available


    February 2021
  90. CHEN HN, Shu Y, Liao F, Liao X, et al
    Genomic evolution and diverse models of systemic metastases in colorectal cancer.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
    PubMed     Abstract available


  91. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.
    PubMed    


  92. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available


    January 2021
  93. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.
    PubMed    


  94. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    


  95. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    PubMed     Abstract available


  96. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    PubMed     Abstract available


    December 2020
  97. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    PubMed     Abstract available


    November 2020
  98. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    PubMed     Abstract available


  99. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.
    PubMed    


    October 2020
  100. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    PubMed     Abstract available


  101. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    PubMed     Abstract available


    September 2020
  102. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    PubMed     Abstract available


  103. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.
    PubMed    


    February 2020
  104. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available


    January 2020
  105. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: